These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10096976)

  • 1. Heparin-coated cardiopulmonary bypass equipment. I. Biocompatibility markers and development of complications in a high-risk population.
    Videm V; Mollnes TE; Fosse E; Mohr B; Bergh K; Hagve TA; Aasen AO; Svennevig JL
    J Thorac Cardiovasc Surg; 1999 Apr; 117(4):794-802. PubMed ID: 10096976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin-coated cardiopulmonary bypass equipment. II. Mechanisms for reduced complement activation in vivo.
    Videm V; Mollnes TE; Bergh K; Fosse E; Mohr B; Hagve TA; Aasen AO; Svennevig JL
    J Thorac Cardiovasc Surg; 1999 Apr; 117(4):803-9. PubMed ID: 10096977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes : a European multicentre study.
    Fosse E; Thelin S; Svennevig JL; Jansen P; Mollnes TE; Hack E; Venge P; Moen O; Brockmeier V; Dregelid E; Haldén E; Hagman L; Videm V; Pedersen T; Mohr B
    Eur J Cardiothorac Surg; 1997 Feb; 11(2):320-7. PubMed ID: 9080162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial.
    Muehrcke DD; McCarthy PM; Kottke-Marchant K; Harasaki H; Pierre-Yared J; Borsh JA; Ogella DA; Cosgrove DM
    J Thorac Cardiovasc Surg; 1996 Aug; 112(2):472-83. PubMed ID: 8751516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement and granulocyte activation in two different types of heparinized extracorporeal circuits.
    Ovrum E; Mollnes TE; Fosse E; Holen EA; Tangen G; Abdelnoor M; Ringdal MA; Oystese R; Venge P
    J Thorac Cardiovasc Surg; 1995 Dec; 110(6):1623-32. PubMed ID: 8523872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High and low heparin dose with heparin-coated cardiopulmonary bypass: activation of complement and granulocytes.
    Ovrum E; Mollnes TE; Fosse E; Holen EA; Tangen G; Ringdal MA; Videm V
    Ann Thorac Surg; 1995 Dec; 60(6):1755-61. PubMed ID: 8787476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment.
    Fukutomi M; Kobayashi S; Niwaya K; Hamada Y; Kitamura S
    Artif Organs; 1996 Jul; 20(7):767-76. PubMed ID: 8828766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass.
    Gorman RC; Ziats N; Rao AK; Gikakis N; Sun L; Khan MM; Stenach N; Sapatnekar S; Chouhan V; Gorman JH; Niewiarowski S; Colman RW; Anderson JM; Edmunds LH
    J Thorac Cardiovasc Surg; 1996 Jan; 111(1):1-11; discussion 11-2. PubMed ID: 8551753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disparity in blood activation by two different heparin-coated cardiopulmonary bypass systems.
    Moen O; Fosse E; Brockmeier V; Andersson C; Mollnes TE; Høgåsen K; Venge P
    Ann Thorac Surg; 1995 Nov; 60(5):1317-23. PubMed ID: 8526620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Centrifugal pump and heparin coating improves cardiopulmonary bypass biocompatibility.
    Moen O; Fosse E; Dregelid E; Brockmeier V; Andersson C; Høgåsen K; Venge P; Mollnes TE; Kierulf P
    Ann Thorac Surg; 1996 Oct; 62(4):1134-40. PubMed ID: 8823102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass.
    Moen O; Høgåsen K; Fosse E; Dregelid E; Brockmeier V; Venge P; Harboe M; Mollnes TE
    Ann Thorac Surg; 1997 Jan; 63(1):105-11. PubMed ID: 8993250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass.
    Fosse E; Moen O; Johnson E; Semb G; Brockmeier V; Mollnes TE; Fagerhol MK; Venge P
    Ann Thorac Surg; 1994 Aug; 58(2):472-7. PubMed ID: 8067851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin-coated circuits reduce complement activation and inflammatory response to cardiopulmonary bypass.
    Tamim M; Demircin M; Guvener M; Peker O; Yilmaz M
    Panminerva Med; 1999 Sep; 41(3):193-8. PubMed ID: 10568115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of a Duraflo II-coated cardiopulmonary bypass circuit and a trillium-coated oxygenator during open-heart surgery.
    Hoel TN; Videm V; Baksaas ST; Mollnes TE; Brosstad F; Svennevig JL
    Perfusion; 2004 May; 19(3):177-84. PubMed ID: 15298426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement activation during extracorporeal circulation. In vitro comparison of Duraflo II heparin-coated and uncoated oxygenator circuits.
    Svennevig JL; Geiran OR; Karlsen H; Pedersen T; Mollnes TE; Kongsgard U; Frøysaker T
    J Thorac Cardiovasc Surg; 1993 Sep; 106(3):466-72. PubMed ID: 8361189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete heparin-coated cardiopulmonary bypass and low heparin dose reduce complement and granulocyte activation.
    Ovrum E; Fosse E; Mollnes TE; Am Holen E; Tangen G; Abdelnoor M; Ringdal MA; Oystese R; Venge P
    Eur J Cardiothorac Surg; 1996; 10(1):54-60. PubMed ID: 8776186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations.
    Ovrum E; Tangen G; Oystese R; Ringdal MA; Istad R
    J Thorac Cardiovasc Surg; 2001 Feb; 121(2):324-30. PubMed ID: 11174738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations.
    Videm V; Svennevig JL; Fosse E; Semb G; Osterud A; Mollnes TE
    J Thorac Cardiovasc Surg; 1992 Apr; 103(4):806-13. PubMed ID: 1548925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical study of platelet function and coagulation/fibrinolysis with Duraflo II heparin coated cardiopulmonary bypass equipment.
    Nakajima T; Osawa S; Ogawa M; Sasaki T; Izumoto H; Yagi Y; Kawazoe K
    ASAIO J; 1996; 42(4):301-5. PubMed ID: 8828788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A closed perfusion system with heparin coating and centrifugal pump improves cardiopulmonary bypass biocompatibility in elderly patients.
    Lindholm L; Westerberg M; Bengtsson A; Ekroth R; Jensen E; Jeppsson A
    Ann Thorac Surg; 2004 Dec; 78(6):2131-8; discussion 2138. PubMed ID: 15561050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.